PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment

Tian-En Li,Shun Wang,Xiao-Tian Shen,Ze Zhang,Mo Chen,Hao Wang,Ying Zhu,Da Xu,Bei-Yuan Hu,Ran Wei,Yan Zheng,Qiong-Zhu Dong,Lun-Xiu Qin
DOI: https://doi.org/10.3389/fimmu.2020.589997
IF: 7.3
2020-01-01
Frontiers in Immunology
Abstract:Background and Aims:Pyruvate kinase M2 (PKM2) is an essential regulator of the Warburg effect, but its biological function promoting immune escape of hepatocellular carcinoma (HCC) is unclear.Methods:GEPIA web tool and immunohistochemistry (IHC) analysis were employed to evaluate the clinical relevance of PKM2 in HCC patients. Both in vitro CCK-8, colony formation, and transwell assays, and in vivo xenografts were performed to evaluate the malignancy of HCC cells. PKM2 and PD-L1 levels were examined by Western blot, qRT-PCR, and IHC. The role of PKM2 on in vivo immune response was also investigated.Results:PKM2 was significantly upregulated in HCC and associated with a poor prognosis of HCC patients. Knockdown of PKM2 inhibited in vitro proliferation, migration, and invasion of HCC cells, as well as in vivo tumor growth. Strikingly, PKM2 showed a strong correlation with the expression of immune inhibitory cytokines and lymphocyte infiltration in HCC. The overexpression of PKM2 sensitized HCC to immune checkpoint blockade, which enhanced IFN-γ positive CD8 T cells in HCC mice models.Conclusion:PKM2 might be a predictor and a potential therapeutic target for immune checkpoint inhibitors in HCC.
What problem does this paper attempt to address?